Icure Pharmaceutical Incorporation Valuation

Is A175250 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A175250 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A175250's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A175250's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A175250?

Key metric: As A175250 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A175250. This is calculated by dividing A175250's market cap by their current revenue.
What is A175250's PS Ratio?
PS Ratio	1.2x
Sales	₩59.84b
Market Cap	₩73.28b

A175250 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	-8.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A175250's PS Ratio compare to its peers?

The above table shows the PS ratio for A175250 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.8x
A027050 Coreana CosmeticsLtd	0.9x	n/a	₩76.0b
A083660 Csa Cosmic	1.4x	n/a	₩55.7b
A044820 Cosmax BTI	0.1x	n/a	₩81.1b
A016100 Leaders Cosmetics	0.7x	n/a	₩51.5b
A175250 Icure Pharmaceutical Incorporation	1.2x	n/a	₩73.3b

Price-To-Sales vs Peers: A175250 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does A175250's PS Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
A044820 Cosmax BTI	0.1x	n/a	US$57.76m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A175250 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the KR Personal Products industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is A175250's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A175250 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A175250's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeoPharm

₩181.1b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩11,580.00

-11.4%

2.7%

NOVAREXLtd

₩135.1b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,630.00

-4.9%

-30.8%

Cosmax

₩1.5t

Researches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally.

A192820

₩132,500.00

-2.1%

15.5%